Review
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Mar 6, 2018; 7(2): 51-57
Published online Mar 6, 2018. doi: 10.5527/wjn.v7.i2.51
Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
Moomal Tasneem, Carly Mannix, Annette Wong, Jennifer Zhang, Gopala Rangan
Moomal Tasneem, Carly Mannix, Annette Wong, Jennifer Zhang, Gopala Rangan, Centre for Transplant and Renal Research, Westmead Institute for Medical Research, the University of Sydney, Sydney 2145, Australia
Moomal Tasneem, Carly Mannix, Annette Wong, Jennifer Zhang, Gopala Rangan, Department of Renal Medicine, Westmead Hospital, Sydney 2145, Australia
Author contributions: Tasneem M contributed to draft the manuscript, review the literature and the content; Mannix C contributed to draft the manuscript and contributed to the content; Wong A contributed to draft the manuscript and the content; Zhang J contributed to draft the manuscript and contributed to the content; Rangan G contributed to draft the manuscript, review the literature and contributed to the content.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported. Rangan G is recipient of an investigator initiated grant from the Danone Nutricia Research (manufacturer of bottled water).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Gopala Rangan, FRACP, MBBS, PhD, Associate Professor, Staff Nephrologist, Centre for Transplant and Renal Research, Westmead Institute for Medical Research, the University of Sydney, 176 Hawkesbury Road (PO Box 412), Westmead, Sydney 2145, Australia. g.rangan@sydney.edu.au
Telephone: +61-2-86273502
Received: December 18, 2017
Peer-review started: December 18, 2017
First decision: January 23, 2018
Revised: January 29, 2018
Accepted: February 28, 2018
Article in press: February 28, 2018
Published online: March 6, 2018
Core Tip

Core tip: Serum copeptin is correlated with disease severity in autosomal dominant polycystic kidney disease (ADPKD), and predicts future renal events (decline in renal function and increase in total kidney volume). The aim of this review is to critically evaluate the role of copeptin as a prognostic biomarker of renal outcomes in ADPKD, and if it has potential as a predictive marker of treatment response.